-
Augurex Life Sciences Corp. has announced a new partnership with ARUP Laboratories to launch the 14-3-3η (eta) test, aimed at enhancing the early diagnosis and management of rheumatoid arthritis (RA). The 14-3-3η biomarker is associated with more severe RA and higher risk of joint damage, making it a critical tool for early intervention. By expanding access to this test, clinicians across the U.S. can improve personalized care and outcomes for RA patients. This collaboration reflects a shared commitment between Augurex and ARUP to advance autoimmune diagnostics and patient health.
Oct 20, 2024
-
Oct 16, 2024
-
Yourgene Health announces that it has received accreditation under the new EU requirements of the in vitro diagnostic regulation (IVDR) for the Yourgene® Cystic Fibrosis Base assay.
Oct 16, 2024
-
Healthcasts, the leading online community for healthcare professional consultation and real-world experience, today announced the appointment of Max Baumer, CPA, as Chief Operating Officer and Chief Financial Officer. Baumer has spent over a decade overseeing finance and operations for companies experiencing exceptional growth including large hospital systems and healthcare staffing companies, making him uniquely positioned to bridge financial and operational duties in his role at Healthcasts.
Oct 15, 2024
-
Oct 14, 2024
-
AI-Sight – the University of Liverpool AI diagnostic technology spin-out based at Sci-Tech Daresbury – has successfully concluded its seven-figure equity funding round from experienced healthcare industry figures and investors.
Oct 8, 2024
-
Sep 30, 2024
-
CovarsaDx, a prominent Clinical Research Organization (CRO) renowned for its expertise in vitro diagnostics (IVDs) and medical devices, is proud to announce its membership in the Medical Device Innovation Consortium (MDIC). This partnership marks a significant milestone in CovarsaDx’s ongoing mission to advance innovation in healthcare technology by providing reliable clinical validation results from an elite network of experienced investigators.
Sep 30, 2024
-
Duke Street Bio Ltd has announced that the European Medicines Agency (EMA) has granted approval to commence a clinical trial for its highly-selective PARP1 inhibitor, DSB2455.
Sep 23, 2024
-
Medix Biochemica has announced DevCo has completed a capital raise resulting in 616 MEUR of total commitments for its long-term single asset investment vehicle for Medix Biochemica.
Sep 18, 2024
-
MX3's new Heat Stress Management Toolkit helps organizations combat heat-related stress with real-time monitoring and risk mitigation.
Sep 15, 2024
-
eClinical Solutions LLC, a global provider of digital clinical software and services, today announced that GI Partners, a private investment firm, has made a majority investment in the company to advance the future of digital trials via continued enhancements to its leading AI-powered data products and biometrics services.
Sep 11, 2024
-
PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, today announced the launch of MET Predict† on the AISightⓇ† Image management system (IMS). MET Predict is an AI-powered algorithm designed to help pathologists identify non-small cell lung cancer (NSCLC) tumors that may be more likely to have MET exon 14 skipping (METex14) or MET amplification, directly from an H&E whole slide image.
Sep 9, 2024
-
The Verisense Smart Watch, Which Collects Digital Health Data During Clinical Trials, is Now Compatible with Both Apple and Android Smartphones.
Sep 9, 2024
-
Fimlab Laboratories, Finland’s largest provider of laboratory services, research, and training, is taking the next step on its digital pathology journey with Proscia®, a global leader in AI-enabled pathology solutions for precision medicine. The company will use Proscia’s software platform to help its pathologists generate more precise results with artificial intelligence (AI).
Sep 8, 2024
-
Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, will participate in the “This or That? Debating the Role of Panels, Exomes, and Genomes in the Diagnostic Odyssey” Educational Breakout Session (EBS), and will present two posters at the upcoming National Society for Genetic Counselors’ (NSGC) 2024 Annual Meeting taking place September 17 – 21, 2024 at the New Orleans Ernest N. Morial Convention Center in New Orleans, LA. Baylor Genetics will also be exhibiting in booth 427.
Sep 8, 2024
-
Proscia and Smart Reporting have partnered to help pathologists inform treatment decisions.
Sep 4, 2024
-
Indica Labs has announced the Diagnostics & Research Institute for Pathology at the Medical University of Graz has selected the HALO AP® digital pathology platform from Indica Labs to deliver primary diagnostics, alongside Aperio GT 450 scanners from Leica Biosystems.
Sep 5, 2024
-
Indica Labs and Paige have formed a non-exclusive partnership aimed at integrating Paige’s Diagnostic AI models into Indica’s robust Anatomic Pathology workflow management software, HALO AP®.
Aug 28, 2024
-
Baylor Genetics, a joint venture clinical diagnostic laboratory at the forefront of genetic testing, will host a webinar, “RNAseq: Enhancing Rare Disease Insights from WES & WGS,” that will explore the company’s new RNAseq offering and its impact on advancing rare disease insights from Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS).
Aug 28, 2024